CN106188205A - A kind of purposes of novel momordica grosvenori alcohol derivatives monomer and combinations thereof thing - Google Patents
A kind of purposes of novel momordica grosvenori alcohol derivatives monomer and combinations thereof thing Download PDFInfo
- Publication number
- CN106188205A CN106188205A CN201610520359.0A CN201610520359A CN106188205A CN 106188205 A CN106188205 A CN 106188205A CN 201610520359 A CN201610520359 A CN 201610520359A CN 106188205 A CN106188205 A CN 106188205A
- Authority
- CN
- China
- Prior art keywords
- cancer
- tumor
- carcinoma
- momordica grosvenori
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of novel momordica grosvenori alcohol derivatives monomer (4) for treatment and/or prophylaxis of tumours and/or cancer medicine in purposes, and for immunomodulating, improve microcirculation, improve quality of life health product in purposes.Invention further provides compositions of including novel momordica grosvenori alcohol derivatives monomer (4) and application thereof.Novel momordica grosvenori alcohol derivatives monomer (4) has the high antitumor effectiveness of wide spectrum, its activity and effectiveness are superior to tetracyclic triterpene glycoside antitumor medicine/health product Rg3 similar with its structure in the market, and its effectiveness is also above broad-spectrum anti-cancer drug paclitaxel, treatment and/or prevention various cancers and/or the medicine of tumor can be made for, and be used for immunomodulating and/or improve microcirculation and/or improve the health product of quality of life, emphasis is applied to the treatment of malignant tumor, has broad application prospects.
Description
Technical field
The present invention relates to field of medicaments, be specifically related to the use of a kind of novel momordica grosvenori alcohol derivatives monomer and combinations thereof thing
On the way.
Background technology
Cancer is the second-biggest-in-the-world disease torturing human life, and mortality rate is only second to cardiovascular and cerebrovascular disease, is that the mankind are dead
One of main factor died.By World Health Organization organize subordinate IARC of cancer mechanism of official (IARC) bear
Latest edition " report of world's cancer " prediction of duty, global cases of cancer will present rapidly breeds situation, by 2012 14,000,000
People, the most fast 19,000,000 people increasing to 2025, it was up to 24,000,000 people by 2035.Report also shows, within 2012, the whole world is new
Increasing cases of cancer has nearly half to occur in Asia, and wherein most is in China, and the newly-increased cases of cancer height of China ranks first.2012
Newly-increased 3,070,000 cancer patients of China also cause about 2,200,000 people dead, divide and account for the 21.9% and 26.8% of whole world total amount.WHO
The statistics of data slightly below China.2012 annual datas that whole nation tumor Register issues show, China is annual newly-increased
Cases of cancer about 3,500,000, there are about 2,500,000 people the most dead.
The common method for the treatment of of cancer mainly has a Three models now: operation, radiotherapy and Drug therapy, and selected which control
Treatment method then depends on the position of tumor, grade malignancy, development degree and patient body state.In Three models, operation
Therapeutic Method, the invasion of Chang Yinwei cancerous cell spreads to adjacent tissue or far-end transfer and effect is limited;The Therapeutic Method of radiotherapy, then
It is limited to the injury that other normal structures internal are caused;The Therapeutic Method of medicine, pernicious for dispersivity in late period and transitivity
Tumor is most basic Therapeutic Method.In the decades in past, though the chemotherapy being conceived to direct killing tumor cell has significantly
Development and progress, becomes the backbone of tumor pharmacother, but this Therapeutic mode is to breeding solid tumor weak effect, medicine slowly
The defect that selectivity is little, toxicity is many and serious becomes the important limiting factor in clinical treatment.Continue operation, radiation and chemotherapy
The 4th kind of pattern afterwards is the Biotherapeutics of tumor, and it is mainly by tumor host defense mechanism or the effect of biological preparation
Regulate the biologically of body self, thus suppress or eliminate tumor;Although Biotherapeutics not the biggest toxic and side effects, but
Owing to technology requires tight, complex process, therefore price is high, and numerous cancer patients and family members are difficult to bear, and affect it and control in cancer
Popularizing for the treatment of field.
Owing to there is above-mentioned various restriction, the research and development of natural antitumor medicine achieve increasing concern.Natural anti-
Cancer drug either at suppression or killing tumor cell, adjustment body's immunity, improve symptom and feature and alleviate chemicotherapy
In toxic and side effects, or in the conditioning after being ill of tumor, it is respectively provided with important function.Thus, natural plants new therapy will become and continue
The 5th kind of pattern after operation, radiotherapy, chemotherapy and biotherapy.
Fructus Momordicae is a kind of rare medicinal herbs, belongs to the perennial liana of Cucurbitaceae, sweet in the mouth cool in nature.In Fructus Momordicae extract
Containing the saponin constituent of non-saccharide sweet taste, also known as momorside, connect the number of glycosyl according to wherein sapogenin and connect position
The difference put in momorside isolation identification go out Fructus Momordicae bioside, three glucosides, four glucosides, five glucosides, six sugar
The multiple saponin monomer such as glycosides, is respectively designated as mogroside II, III, IV, V, VI (MogrosideII, III, IV, V, VI)
Deng, wherein the sugariness of momordica glycoside V Mogroside V (1A) (as shown in Figure 1) is 256-344 times of sucrose, and Fructus Momordicae is sweet
Sugariness is sucrose 126 times of glycosides IV Mogroside IV (1B) (as shown in Figure 1), its heat is zero, has clearing heat and moistening lung town
Cough, effect of loosening bowel to relieve constipation, obesity, constipation, diabetes etc. are had preventive and therapeutic effect.
Triterpene glucoside Mogrosides be two glucoside side chains being made up of less than four glucose units with β-
Glycosidic bond is connected with C-3, C-24 of sapogenin momordica grosvenori alcohol Mogrol (2) (as shown in Figure 2), the company between pendant glucose
Connecing key is β-1,6 and β-l, 2 glycosidic bonds.
Many studies have shown that, triterpene glucoside can improve glucose and the utilization of fat, increases the sensitivity of insulin, but
The effective ingredient of Fructus Momordicae hypoglycemic activity and mechanism of action are the most indefinite.Hu Lihong seminar of Shanghai institute of materia medica of the Chinese Academy of Sciences
With Shen Xu seminar, the hypoglycemic activity of Fructus Momordicae is studied, first in HepG2 cell, to content in Fructus Momordicae
High momordica glycoside V (1A) is tested, and finds that it does not has activity to AMPK;And momordica grosvenori alcohol Mogrol (2) and derivative
Thing 3 alpha-hydroxy-2 5-dehydroxylation-24-ketone-momordica grosvenori alcohol (3 α-hydroxy-25-dehydroxy-24-oxomogrol) (3)
(as shown in Figure 3) AMPK (Chen X.B., et al can but be activated;Bioorganic&Medicinal Chemistry
2011,19:5776).At present, any patent and document report is not also had to generate sieve under given conditions by momordica grosvenori alcohol (2)
Chinese fruit 01 derivatives monomer (3) and momordica grosvenori alcohol derivatives monomer (4) (as shown in Figure 4), do not have any patent and document report yet
Road there are momordica grosvenori alcohol derivatives monomer (4) with and application thereof.
Summary of the invention
The technical problem to be solved in the present invention is to provide the new application of a kind of novel momordica grosvenori alcohol derivatives monomer (4), this
Invention further provides the new application of the compositions including novel momordica grosvenori alcohol derivatives monomer (4).
The following structure that the present invention provides
Novel momordica grosvenori alcohol derivatives monomer (4), the hyperoxia separated with extracting directly in other most cucurbitaceous plants
Changing calabash alkanes tetracyclic triterpenoids compound different, novel momordica grosvenori alcohol derivatives monomer (4) is protoxydic calabash alkanes Fourth Ring
Triterpenoid, that be characterized on C-3 and C-11 connection is-OH rather than=O, and degree of oxidation lowers significantly, at present cannot
Directly extracting and developing from Genus Siraitia Merr, it is difficult to preparation.
First aspect present invention provides following structure
One purposes of novel momordica grosvenori alcohol derivatives monomer (4), shows that preparation is for treatment and/or prophylaxis of tumours
And/or the purposes in the medicine of cancer.
In a preference, wherein said tumor and/or cancer are selected from:
Malignant tumor, including bladder cancer, breast carcinoma, colon cancer, renal carcinoma, hepatocarcinoma, pulmonary carcinoma, head and neck cancer, the esophageal carcinoma, gallbladder
Cancer, ovarian cancer, cancer of pancreas, gastric cancer, cervical cancer, thyroid carcinoma, carcinoma of prostate and skin carcinoma;
Lymphoid hematopoetic tumor, including leukemia, acute lymphoblastic leukemia, the white blood of acute lymphoblast
Disease, B-cell lymphom, T-cell lymphom, Huo Qijin lymphatic cancer, non-Huo Qijin lymphatic cancer, hairy cell lymphom, overcoat are thin
Born of the same parents' lymphoma, myeloma and Burkett ' sShi lymphatic cancer;
The hematopoetic tumor of bone marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and
Promyelocytic leukemia;
The tumor of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma;
Maincenter and the tumor of peripheral nervous system, including astrocytoma, become neurofibroma, glioma and nerve
Sheath tumor;And
Other tumors, including melanoma, spermocytoma, teratocarcinoma, osteosarcoma, exophytic pigment neck tumor, thyroid filter
Capsule cancer and Kaposi's sarcoma.
Second aspect present invention provides following structure
Another purposes of novel momordica grosvenori alcohol derivatives monomer (4), show that preparation for immunomodulating and/or changes
Purposes in the health product of kind microcirculation and/or raising quality of life.
Third aspect present invention provides a use of the compositions comprising above-mentioned novel momordica grosvenori alcohol derivatives monomer (4)
On the way, the purposes prepared in the medicine for the treatment of and/or prophylaxis of tumours and/or cancer is shown;In a preference, described
Tumor and/or cancer are selected from:
Malignant tumor, (includes small cell lung cancer, non-little including bladder cancer, breast carcinoma, colon cancer, renal carcinoma, hepatocarcinoma, pulmonary carcinoma
Cell lung cancer), head and neck cancer, the esophageal carcinoma, carcinoma of gallbladder, ovarian cancer, cancer of pancreas, gastric cancer, cervical cancer, thyroid carcinoma, prostate
Cancer and skin carcinoma (including squamous cell carcinoma);
Lymphoid hematopoetic tumor, including leukemia, acute lymphoblastic leukemia, the white blood of acute lymphoblast
Disease, B-cell lymphom, T-cell lymphom, Huo Qijin lymphatic cancer, non-Huo Qijin lymphatic cancer, hairy cell lymphom, overcoat are thin
Born of the same parents' lymphoma, myeloma and Burkett ' sShi lymphatic cancer;
The hematopoetic tumor of bone marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and
Promyelocytic leukemia;
The tumor of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma;
Maincenter and the tumor of peripheral nervous system, including astrocytoma, become neurofibroma, glioma and nerve
Sheath tumor;And
Other tumors, including melanoma, spermocytoma, teratocarcinoma, osteosarcoma, exophytic pigment neck tumor, thyroid filter
Capsule cancer and Kaposi's sarcoma.
In a preference, described compositions is pharmaceutical preparation, and it comprises treatment and/or prevents the described novel of effective dose
Momordica grosvenori alcohol derivatives monomer (4) and optional pharmaceutically acceptable diluent, carrier, excipient, adjuvant or vehicle.
In a preference, the dosage form of described pharmaceutical preparation is in peroral dosage form, injection type or Topical application forms
Any;
In a preference, described peroral dosage form includes tablet, powder, suspension, emulsion, capsule, granule, sugar-coat
Sheet, pill, liquid, spirit, syrup or limonada;
In a preference, described injection type includes water preparation, suspension or solution;
In a preference, described Topical application forms includes ointment, solid, suspension, water preparation, spirit, powder, paste
Agent, suppository, aerosol, paste, liniment, lotion, enema or Emulsion.Fourth aspect present invention provide comprise above-mentioned newly
Another purposes of the compositions of type momordica grosvenori alcohol derivatives monomer (4), it is provided that comprise above-mentioned novel momordica grosvenori alcohol derivant
One purposes of the compositions of monomer (4),
Described compositions is a kind of health product, and its described novel momordica grosvenori alcohol comprising treatment and/or prevention effective dose spreads out
Acceptable carrier in biomonomer (4) and optional health product.
Terminology used in the present invention has defined below, unless otherwise described:
Term used herein " momordica grosvenori alcohol derivatives monomer (3) " means 3 alpha-hydroxy-2 5-dehydroxylation-24-ketone-arhat
Really alcohol (3 α-hydroxy-25-Dehydroxy-24-oxomogrol) (structural formula is as shown in Figure 3);Term used herein is " new
Type momordica grosvenori alcohol derivatives monomer (4) " mean 3 alpha-hydroxy-2s 2,24-diene-24,25-dehydroxylation-momordica grosvenori alcohol (3 α-
Hydroxy-22,24-diene-24,25-dehydroxy-mogrol) (4) (structural formula is as shown in Figure 4).
Term used herein " compositions " means to include to comprise each product specifying composition of specified amount, and directly or
Any product indirectly produced from each combination specifying composition of specified amount.Described Topical application forms includes ointment, solid, hangs
Turbid liquid, water preparation, spirit, powder, paste, suppository, aerosol, paste, liniment, lotion, enema or Emulsion.At aseptic bar
By reactive compound and pharmaceutically acceptable carrier and any required preservative, buffer agent or propellants under part.Ophthalmically acceptable
Preparation, eye ointment, powder and solution are contemplated within the scope of the present invention.
When for above-mentioned treatment or other treatment, treat and/or prevent a kind of the compounds of this invention of effective dose permissible
Apply in a pure form, or with pharmaceutically acceptable salt, ester or prodrug forms (in the case of there are these forms) application.Or
Person, described compound can be with the pharmaceutical composition containing this purpose compound Yu one or more pharmaceutically acceptable excipient
It is administered.The compounds of this invention that word " is treated and/or prevents effective dose " refer to be applicable to the reasonable effect of any therapeutic treatment/
The compound of the q.s of Hazard ratio treatment obstacle.It is to be understood that total consumption per day of the compounds of this invention and compositions must be by
Attending physician makes decision in the range of reliable medical judgment.For any concrete patient, concrete treatment and/or prevention
Depending on effective dose level must be according to many factors, described factor includes the order of severity of treated obstacle and this obstacle;Institute
The activity of the particular compound used;The concrete compositions used;The age of patient, body weight, general health, sex and
Diet;The administration time of the particular compound used, route of administration and excretion rate;The treatment persistent period;With the tool used
The medicine that body compound is applied in combination or uses simultaneously;And similar factor known to medical field.Such as, the way of this area
It is that the dosage of compound, from the beginning of the level required less than obtaining required therapeutic effect, is gradually increased dosage, until obtaining
Required effect.
The present invention also provide for comprising optionally diluent acceptable with one or more non-toxic pharmaceutical, carrier, excipient,
Adjuvant or the pharmaceutical preparation of vehicle the compounds of this invention formulated together.Described pharmaceutical preparation can especially particular formulation become with
Solid or liquid form is for oral administration, for parental injection or for rectally.
The pharmaceutical composition of the present invention can by oral, rectum, parenteral, pond, intravaginal, intraperitoneal, locally (as led to
Cross powder, ointment or drop), buccal give the mankind and other mammals, or as oral spray or nasal spray
Agent gives.Terms used herein " parenteral " refers to include intravenous, intramuscular, intraperitoneal, breastbone interior, subcutaneous and intra-articular injection
Administering mode with transfusion.
In yet another aspect, the present invention provides and comprises present component and the pharmaceutical composition of physiologically tolerable diluent.
The present invention includes one or more above-claimed cpds, its with one or more nontoxic physiologically tolerable or acceptable diluent,
Carrier, adjuvant or vehicle (herein they being referred to as diluent) are configured to compositions, together for parental injection, intranasal
Transmit, with solid or liquid form oral administration, rectum or topical etc..
The compositions being suitable for parental injection can include physiologically acceptable sterile, aqueous or non-aqueous liquor, dispersion
Agent, suspensoid or Emulsion, and for reconstructing the sterile powders of sterile injectable solution agent or dispersant.The most aqueous or non-aqueous
The example of carrier, diluent, solvent or vehicle includes water, ethanol, polyhydric alcohol (propylene glycol, Polyethylene Glycol, glycerol etc.), plant
Oil (such as olive oil), injectable organic ester such as ethyl oleate and their suitable mixture.
These compositionss also can contain adjuvant, such as preservative, wetting agent, emulsifying agent and dispersant.By various antibacteriums
Agent and antifungal, such as parabens, chlorobutanol, phenol, sorbic acid etc., it can be ensured that prevent the effect of microorganism.
It is also expected to include isotonic agent, such as saccharide, sodium chloride etc..By use can postpone absorption material, such as aluminum monostearate with
Gelatin, the prolongation that can reach injectable drug form absorbs.
Suspensoid the most also can contain suspending agent, such as ethoxylation i-octadecanol, polyoxyethylene mountain
Pears alcohol and polyoxyethylene sorbitan esters, microcrystalline Cellulose, inclined aluminium hydroxide, bentonite, agar and Tragacanth or this
The mixture etc. of a little materials.
In some cases, for extending the effect of medicine, it is desirable to slow down and subcutaneously or intramuscularly inject the absorption of medicine.This can lead to
Cross and use the crystal of poorly water-soluble or the liquid suspension of amorphous substance to realize.So, the infiltration rate of medicine depends on
Its dissolution velocity, and dissolution velocity can be depending on crystal size and crystal formation.Or, the delay of the medicament forms of parenteral
Absorb by by this medicine dissolution in or be suspended in oil vehicle in realize.
Injectable depot formulations form can be by biodegradable polymer such as polylactide-polyglycolide
(polylactide-polyglycolide) prepared by the microcapsule matrix forming medicine in.Can according to medicine and polymer it
Than the character with the concrete polymer used, drug releasing rate is controlled by.The reality of other biological degradable polymer
Example includes poe class (poly (orthoesters)) and polyanhydrides (poly (anhydrides)).Injectable depot formulations
Also can be can prepare by the liposome compatible with bodily tissue or microemulsion by pharmaceutical pack is embedded in.
Injectable formulation can be such as by filtering with bacteria filter or by mixing the biocide of aseptic solid composite form
Carrying out sterilizing, described solid composite can be dissolved or dispersed in sterilized water or other sterile injectable medium before use.
Solid dosage forms for oral administration includes capsule, tablet, pill, powder and granule.In this type of solid dosage forms
In, reactive compound can be with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate
And/or the mixing of following material: a) filler or extender such as starch, lactose, sucrose, glucose, mannitol and silicic acid;B) viscous
Mixture such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and Radix Acaciae senegalis;C) wetting agent is the sweetest
Oil;D) disintegrating agent such as agar, calcium carbonate, Rhizoma Solani tuber osi or tapioca, alginic acid, some silicate and sodium carbonate;E) solution resistance
Stagnant dose such as paraffin;F) accelerator such as quaternary ammonium compound is absorbed;G) wetting agent such as spermol and glyceryl monostearate;H) adsorbent
Such as Kaolin and bentonite and i) lubricant such as Pulvis Talci, calcium stearate, magnesium stearate, solid polyethylene glycol, dodecyl
Sodium sulfate and their mixture.In the case of capsule, tablet and pill, described dosage form also can comprise buffer agent.
The solid composite of similar type uses excipients such as lactose and high molecular weight polyethylene glycol etc., it is possible to as soft
Implant in capsule and hard capsule.
The solid dosage forms of tablet, dragee (dragees), capsule, pill and granule can with coating and shell material such as
Prepare together with enteric coating material other clothing materials known with field of medicine preparations.These solid dosage formss can optionally contain opacifier, and
Its composition also can make its simply or preferentially at certain position of intestinal optionally with delayed mode release of active ingredients.Can use
The example of embedding composition include polymer substance and wax class.If be suitable for, reactive compound also can with on one or more
State excipient and be made into microencapsulated form.
Liquid dosage form for oral administration includes pharmaceutically acceptable Emulsion, solution, suspensoid, syrup and elixir.
Liquid dosage form also can be containing inert diluent commonly used in the art except containing active ingredient beyond the region of objective existence, and such as water or other solvents increase
Solvent and emulsifying agent such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3-fourth two
Alcohol, dimethylformamide, oils (particularly Oleum Gossypii semen, Oleum Arachidis hypogaeae semen, Semen Maydis oil, germ oil, olive oil, Oleum Ricini and Semen Sesami
Oil), glycerol, tetrahydrofurfuryl alcohol (tetrahydrofurfuryl alcohol), Polyethylene Glycol and the fatty acid of sorbitan
Ester and their mixture.Orally administered composition also can comprise adjuvant in addition to comprising inert diluent, such as wetting agent, emulsifying and outstanding
Floating agent, sweeting agent, correctives and flavouring agent.
Compositions for rectum or vagina administration is preferably suppository.Suppository can by by the compounds of this invention with the most non-
Prepared by the mixing of zest excipient or carrier such as cocoa butter, Polyethylene Glycol or suppository wax, they are at room temperature solid, but
It is the most then liquid, therefore can melt in rectal cavity or vaginal canal and discharge reactive compound.
The compounds of this invention can also be administered by liposomal form.As it is known in the art, liposome generally with phospholipid or its
He prepares by lipid material.Liposome is formed by the single or multiple lift aquation liquid crystal being scattered in water-bearing media.Any can shape
Become liposome nontoxic, physiologically acceptable and metabolizable lipid all can use.The present composition of liposomal form removes
Outside containing the compounds of this invention, also can contain stabilizer, preservative, excipient etc..Preferably lipid is natural and the phosphorus of synthesis
Fat and phosphatidylcholine (lecithin), they can use individually or together.The method forming liposome is well known in the art.
Term used herein " pharmaceutically acceptable prodrug " represents the prodrug of the compounds of this invention, and it is in reliable medical science
It is suitable for occurring without with the mankind and zootic contact tissue excessive toxicity, stimulation, anaphylaxis in determination range
Deng, match with rational effect/Hazard ratio and effective to its intended purpose, the most also represent the compounds of this invention
Zwitterionic form.The prodrug of the present invention such as can be rapidly converted into the parent of above formula by hydrolyzing in blood in vivo
Compound.
Novel momordica grosvenori alcohol derivatives monomer (4) in the present invention has suppression human tumor cells (having surveyed cancerous cell for 23 kinds)
And the anti-tumor activity of cell proliferation of human umbilical vein, treatment and/or prevention various cancers can be made for and/or swell
The medicine of tumor, and be used for immunomodulating and/or improve microcirculation and/or improve the health product of quality of life, emphasis is applied to
The treatment of malignant tumor, has broad application prospects.
Accompanying drawing explanation
Fig. 1 is momordica glycoside V (1A), the schematic arrangement of VI (1B).
Fig. 2 is the schematic arrangement of momordica grosvenori alcohol Mogrol (2).
Fig. 3 is the schematic arrangement of momordica grosvenori alcohol derivatives monomer (3).
Fig. 4 is the schematic arrangement of novel momordica grosvenori alcohol derivatives monomer (4).
Detailed description of the invention
Unless specifically indicated, the general sense during term used herein has art of the present invention.
Below with reference to specific embodiment, the present invention will be described, it should be noted that these embodiments are only explanation
Property, and be not considered as limiting the invention.Unreceipted concrete technology or condition in embodiment, according in this area
Technology or condition described by document or carry out according to product description.Agents useful for same or instrument unreceipted production firm person,
Be can by city available from conventional products.
Embodiment 1: prepare momordica grosvenori alcohol derivatives monomer (3) and (4) from the extract of momorside 98%
By Fructus Momordicae extract 50g, (momorside 98%, containing 55% mogroside V, is bought in Guilin Rhein biological
Science and Technology Co., Ltd.) aqueous solution (volume ratio of second alcohol and water is 1:1) of ethanol that adds 250mL (adjusts with hydrochloric acid in advance
Joint to pH value is 3.0), stirring and dissolving in a kettle., then heat to heat 2 hours at 120 DEG C, be cooled to room temperature 25 DEG C
After, it is 7 that the NaOH alkali liquor of reactant liquor 1M is neutralized to pH value, is steamed by ethanol at 90-95 DEG C as far as possible, and remaining concentrated solution adds
Enter 200mL distilled water, cool down after being sufficiently stirred for, stand, water layer above is separated and discards, obtain coffee-like extractum;Use respectively
The coffee-like extractum of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, after merging 3 extracts, with rotating at 100-120 DEG C
Evaporimeter concentrates, and ethyl acetate is evaporated completely, i.e. obtains containing momordica grosvenori alcohol derivatives monomer (3) and momordica grosvenori alcohol derivant list
The light coffee color solid 18.2g of body (4);With ethanol, light coffee color solid is loaded into silicagel column, with acetonitrile: water (volume ratio 20:1)
Gradient elution, collects different effluent sequentially, obtains A (6.8g), B (5.6g) two component after concentration;First collect
A (6.8g) the component recycle silicon glue post arrived separates (chloroform: ethanol/60:5 eluting), obtains momordica grosvenori alcohol derivatives monomer (3)
4.1g (HPLC > 99%).ESIMS m/z 503(458+45)[M+HCOO-]-(calcd for C31H51O5);13C-NMR
(600MHz, MeOD) δ ppm:29.1 (C-1),
31.7(C-2),79.4(C-3),42.8(C-4),144.1(C-5),120.7(C-6),25.2(C-7),44.8(C-
8),41.1(C-9),35.4(C-10),77.7(C-11),30.6(C-12),48.3(C-13),49.6(C-14),34.9(C-
15),27.5(C-16),50.7(C-17),17.2(C-18),26.6(C-19),41.1(C-20),19.0(C-21),37.8(C-
22),40.3(C-23),218.2(C-24),35.4(C-25),18.8(C-26),18.8(C-27),26.4(C-28),19.9
(C-29),19.3(C-30);3a-hydroxyl-25-dehydroxylation-24-carbonyl-momordica grosvenori alcohol (3a-hydroxy-with document report
25-Dehydroxy-24-oxomogrol) carbon modal data compares, the two basically identical (Chen X.B., et al;
Bioorganic&Medicinal Chemistry 2011,19:5776)。
B (5.6g) the component recycle silicon glue post that rear collection obtains separates (petroleum ether: ethyl acetate/5:2 eluting), obtains sieve
Chinese fruit 01 derivatives monomer (4).3.2g (HPLC > 99%).ESIMS m/z 441[M+H]+(calcd for C30H49O2);13C-
NMR (600MHz, MeOD) δ ppm:23.5 (C-1), 29.5 (C-2), 87.8 (C-3), 44.2 (C-4), 144.1 (C-5), 121.8
(C-6),25.5(C-7),40.9(C-8),40.8(C-9),51.3(C-10),71.9(C-11),41.5(C-12),48.2(C-
13),52.2(C-14),35.3(C-15),24.9(C-16),54.3(C-17),15.2(C-18),18.6(C-19),40.2(C-
20),20.3(C-21),137.4(C-22),128.8(C-23),125.4(C-24),143.3(C-25),19.7(C-26),
25.7(C-27),21.7(C-28),21.7(C-29),18.6(C-30)。
Embodiment 2: prepare momordica grosvenori alcohol derivatives monomer (3) and (4) from the extract of momorside 95%
By Fructus Momordicae extract 50g, (momorside 95%, containing 45% mogroside V, from Guilin Rhein biotechnology
Limited company buys) aqueous solution (volume ratio of first alcohol and water is 3:2) of methanol that adds 250mL (adjusts with sulphuric acid in advance
Joint to pH value is 2.8), stirring and dissolving in a kettle., then heat to heating 2 hours at 120 DEG C, after being cooled to room temperature, instead
It is 7 that the KOH alkali liquor answering liquid 1M is neutralized to pH value, is steamed by methanol at 90-95 DEG C as far as possible, and remaining concentrated solution adds
200mL distilled water, cools down after being sufficiently stirred for, stands, and is separated by water layer above and discards, and obtains coffee-like extractum;Use respectively
The coffee-like extractum of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, after merging 3 extracts, with rotating at 100-120 DEG C
Evaporimeter concentrates, and ethyl acetate is evaporated completely, i.e. obtains containing momordica grosvenori alcohol derivatives monomer (3) and momordica grosvenori alcohol derivant list
The light coffee color solid 15.5g of body (4);With methanol, light coffee color solid is loaded into silicagel column, with acetonitrile: water (19:1) gradient is washed
De-, collect different effluent sequentially, after concentration, obtain A (6.0g), B (5.2g) two component;First collect the A obtained
(6.0g) component recycle silicon glue post separates (chloroform: ethanol/60:5 eluting), obtains momordica grosvenori alcohol derivatives monomer (3) 3.9g
(HPLC > 99%);HPLC、13C-NMR, ESIMS testing result is consistent with the compound (3) in embodiment 1.The B that rear collection obtains
(5.2g) component recycle silicon glue post separates (petroleum ether: ethyl acetate/3:1 eluting), obtains momordica grosvenori alcohol derivatives monomer (4).
3.0g (HPLC > 99%);HPLC、13Momordica grosvenori alcohol derivatives monomer (4) one in C-NMR, ESIMS testing result and embodiment 1
Cause.
Embodiment 3: prepare momordica grosvenori alcohol derivatives monomer (3) and (4) from the extract of momorside 90%
By Fructus Momordicae extract 50g, (momorside 90%, containing 40% mogroside V, from Guilin Rhein biotechnology
Limited company buys) aqueous solution (volume ratio of normal propyl alcohol and water is 2:3) of normal propyl alcohol that adds 250mL (uses first in advance
Acid regulation is 3.2 to pH value, stirring and dissolving in a kettle., then heats to heat 2 hours at 120 DEG C, after being cooled to room temperature,
It is 7 that the NaOH alkali liquor of reactant liquor 1M is neutralized to pH value, is steamed by normal propyl alcohol at 90-95 DEG C as far as possible, and remaining concentrated solution adds
Enter 200mL distilled water, cool down after being sufficiently stirred for, stand, water layer above is separated and discards, obtain coffee-like extractum;Use respectively
The coffee-like extractum of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, after merging 3 extracts, with rotating at 100-120 DEG C
Evaporimeter concentrates, and ethyl acetate is evaporated completely, i.e. obtains containing momordica grosvenori alcohol derivatives monomer (3) and momordica grosvenori alcohol derivant list
The light coffee color solid 14.2g of body (4);With methanol/ethanol, light coffee color solid is loaded into silicagel column, with acetonitrile: water (20:1)
Gradient elution, collects different effluent sequentially, obtains A (5.4g), B (4.3g) two component after concentration;First collect
A (5.4g) the component recycle silicon glue post arrived separates (chloroform: ethanol/60:5 eluting), obtains momordica grosvenori alcohol derivatives monomer (3)
3.5g (HPLC > 99%);HPLC、13C-NMR, ESIMS testing result is consistent with the compound (3) in embodiment 1.After collect
B (4.3g) the component recycle silicon glue post arrived separates (petroleum ether: ethyl acetate/6:4 eluting), obtains momordica grosvenori alcohol derivatives monomer
(4) 2.8g (HPLC > 99%);HPLC、13Momordica grosvenori alcohol derivatives monomer in C-NMR, ESIMS testing result and embodiment 1
(4) consistent.
Embodiment 4: prepare momordica grosvenori alcohol derivatives monomer (3) and (4) from the extract of momorside 80%
By Fructus Momordicae extract 50g, (momorside 80%, containing 20% mogroside V, from Guilin Rhein biotechnology
Limited company buys) aqueous solution (volume ratio of second alcohol and water is 1:1) of ethanol that adds 250mL (uses ethanedioic acid in advance
Regulation to pH value is 2.6), stirring and dissolving in a kettle., then heat to heat 2 hours at 120 DEG C, after being cooled to room temperature,
The Na of reactant liquor 1M2CO3It is 7 that alkali liquor is neutralized to pH value, is steamed by ethanol at 90-95 DEG C as far as possible, and remaining concentrated solution adds
200mL distilled water, cools down after being sufficiently stirred for, stands, and is separated by water layer above and discards, and obtains coffee-like extractum;Use respectively
The coffee-like extractum of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, after merging 3 extracts, with rotating at 100-120 DEG C
Evaporimeter concentrates, and ethyl acetate is evaporated completely, i.e. obtains containing momordica grosvenori alcohol derivatives monomer (3) and momordica grosvenori alcohol derivant list
The light coffee color solid 8.8g of body (4);With methanol/ethanol, light coffee color solid is loaded into silicagel column, with acetonitrile: water (95:5) is terraced
Degree eluting, collects different effluent sequentially, obtains A (3.8g), B (3.0g) two component after concentration;First collect and obtain
A (3.8g) component recycle silicon glue post separate (chloroform: ethanol/60:5 eluting), obtain momordica grosvenori alcohol derivatives monomer (3) 2.1g
(HPLC > 99%);HPLC、13C-NMR, ESIMS testing result is consistent with the compound (3) in embodiment 1.The B that rear collection obtains
(3.0g) component recycle silicon glue post separates (petroleum ether: ethyl acetate/4:1 eluting), obtains momordica grosvenori alcohol derivatives monomer (4)
1.8g (HPLC > 99%);HPLC、13Momordica grosvenori alcohol derivatives monomer (4) one in C-NMR, ESIMS testing result and embodiment 1
Cause.
Embodiment 5: momordica grosvenori alcohol derivatives monomer (4) suppression cell proliferation experiment
Laboratory sample:
Testing drug: the momordica grosvenori alcohol derivatives monomer (4) that embodiment 1 prepares;
Control drug: paclitaxel (SELLECK;Cat.#S1150);Ginsenoside monomer Rg3 is (from source, Shanghai leaf biology section
Skill company limited buys, and commodity article No. is B21059).
Experimental procedure:
It is experiment cell with 24 kinds of cell lines (including 23 kinds of tumor cell lines and a kind of Human umbilical vein endothelial cells system)
System, take the logarithm trophophase cell (3x104/ mL to 2.5x105/ mL), it is seeded in 96 orifice plates with every hole 100 μ L, each cell line
With 96 orifice plates;Then, in addition to control drug paclitaxel, take 7 logarithmic decreases with high concentration 150 μMs to low concentration 2 μMs
Concentration (each concentration sets two multiple holes), is separately added into testing drug solution and control drug solution 500nL (testing drug solution
Or the preparation of control drug solution: be respectively adopted testing drug or control drug be dissolved in 0.5% DMSO solution).Adding of paclitaxel
Entering concentration is by 7 three times of decreasing concentration of high concentration 1 μM to low concentration 0.0014 μM.After tested/control drug solution effects
After 72 hours, use(Promega;Cat.#G7573) luminescent cell viability examination method obtains each cell line
In each concentration of every kind of medicine be the Proliferation Ability percentage rate of cell to this, and draw dose-effect relationship figure, finally according to figure
Middle curve measuring and calculating IC50The highest inhibition percentage (Emax), as shown in Table 1 and Table 2.
Table 1: momordica grosvenori alcohol derivatives monomer (4) and comparison medicine Rg3 suppress cell-proliferation activity laboratory test results.
Table 2: momordica grosvenori alcohol derivatives monomer (4) and comparison medicine paclitaxel, Rg3 suppression cell proliferation effectiveness experiment inspection
Survey result.
SPSS Statistics software (supplier: IBM corporation, software version: XL fit 21) is used to carry
For statistical analysis.
With assuming that variance unequal independent sample inspection (independent-sample T-test) detects medicine group
Statistically significant (P < 0.05 or P < 0.01) whether is presented with the difference of matched group meansigma methods.
Analysis result:
The momordica grosvenori alcohol derivatives monomer (4) the most of the present invention average IC50 in 24 cell line and control drug Radix Ginseng soap
When the glycosides monomer Rg3 average IC50 in 24 cell line compares, difference presents statistically significant (P < 0.05 P < 0.01 simultaneously).
The momordica grosvenori alcohol derivatives monomer (4) the most of the present invention the highest average inhibition percentage in 24 cell line with compare
Drug taxol and the control drug ginsenoside monomer Rg3 the highest average inhibition percentage in 24 cell line compares
Time, difference presents statistically significant (P < 0.05 P < 0.01 simultaneously).
Conclusion:
The momordica grosvenori alcohol derivatives monomer (4) the most of the present invention suppression cell-proliferation activity in all 24 kinds of surveyed cell lines
It is above the similar control drug ginsenoside monomer Rg3 (IC of momordica grosvenori alcohol derivatives monomer (4)50Less than ginsenoside monomer
The IC of Rg350)。
2., in all tested cell lines, momordica grosvenori alcohol derivatives monomer (4) of the present invention is at people's umbilical blood venous endothelial cell
It is that HUVEC has the highest suppression cell-proliferation activity (IC50=10.72 μMs), show its powerful Antineoplastic angiogenesis
Potentiality;Momordica grosvenori alcohol derivatives monomer (3) suppresses cell-proliferation activity to come next in Colon and rectum gland cell system HCT-8
(IC50=14.83 μMs).
The momordica grosvenori alcohol derivatives monomer (4) the most of the present invention the highest suppression ratio (effectiveness) to all 24 kinds of tested cell lines
The most closely 100%;And compare medicine paclitaxel and ginsenoside monomer Rg3 in the 24 kinds of cell lines surveyed, all only to 2 kinds
Cell line has the suppression ratio of nearly 100%.This show the effectiveness of momordica grosvenori alcohol derivatives monomer (4) apparently higher than control drug,
And its high anticancer effectiveness is applicable to many carcinoids kind.
Claims (10)
1. there is following structural formula:
Novel momordica grosvenori alcohol derivatives monomer (4) preparation for treatment and/or prophylaxis of tumours and/or cancer medicine in
Purposes.
Purposes the most according to claim 1, it is characterised in that wherein said tumor and/or cancer are selected from:
Malignant tumor, including bladder cancer, breast carcinoma, colon cancer, renal carcinoma, hepatocarcinoma, pulmonary carcinoma, head and neck cancer, the esophageal carcinoma, carcinoma of gallbladder,
Ovarian cancer, cancer of pancreas, gastric cancer, cervical cancer, thyroid carcinoma, carcinoma of prostate and skin carcinoma;
Lymphoid hematopoetic tumor, including leukemia, acute lymphoblastic leukemia, Acute Lymphoblastic Leukemia, B-
Cell lymphom, T-cell lymphom, Huo Qijin lymphatic cancer, non-Huo Qijin lymphatic cancer, hairy cell lymphom, Mantle Cell drench
Bar tumor, myeloma and Burkett ' sShi lymphatic cancer;
The hematopoetic tumor of bone marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and front marrow
Cell leukemia;
The tumor of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma;
Maincenter and the tumor of peripheral nervous system, including astrocytoma, become neurofibroma, glioma and nerve sheath
Tumor;And
Other tumors, including melanoma, spermocytoma, teratocarcinoma, osteosarcoma, exophytic pigment neck tumor, thyroid filter capsule cancer
And Kaposi's sarcoma.
3. there is following structural formula:
Novel momordica grosvenori alcohol derivatives monomer (4) preparation for immunomodulating and/or improve microcirculation and/or improve life
Purposes in the health product of quality.
4. include following structural formula:
The compositions of novel momordica grosvenori alcohol derivatives monomer (4) at preparation treatment and/or prophylaxis of tumours and/or the medicine of cancer
In purposes.
Purposes the most according to claim 4, it is characterised in that wherein said tumor and/or cancer are selected from:
Malignant tumor, (includes small cell lung cancer, non-small cell including bladder cancer, breast carcinoma, colon cancer, renal carcinoma, hepatocarcinoma, pulmonary carcinoma
Pulmonary carcinoma), head and neck cancer, the esophageal carcinoma, carcinoma of gallbladder, ovarian cancer, cancer of pancreas, gastric cancer, cervical cancer, thyroid carcinoma, carcinoma of prostate and
Skin carcinoma (includes squamous cell carcinoma);
Lymphoid hematopoetic tumor, including leukemia, acute lymphoblastic leukemia, Acute Lymphoblastic Leukemia, B-
Cell lymphom, T-cell lymphom, Huo Qijin lymphatic cancer, non-Huo Qijin lymphatic cancer, hairy cell lymphom, Mantle Cell drench
Bar tumor, myeloma and Burkett ' sShi lymphatic cancer;
The hematopoetic tumor of bone marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and front marrow
Cell leukemia;
The tumor of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma;
Maincenter and the tumor of peripheral nervous system, including astrocytoma, become neurofibroma, glioma and nerve sheath
Tumor;And
Other tumors, including melanoma, spermocytoma, teratocarcinoma, osteosarcoma, exophytic pigment neck tumor, thyroid filter capsule cancer
And Kaposi's sarcoma.
Purposes the most according to claim 5, it is characterised in that said composition is pharmaceutical preparation, it comprises treats and/or pre-
Novel momordica grosvenori alcohol derivatives monomer (4) described in the claim 1 of anti-effective dose and optional pharmaceutically acceptable diluent,
Carrier, excipient, adjuvant or vehicle.
Purposes the most according to claim 6, it is characterised in that the dosage form of described pharmaceutical preparation is peroral dosage form, injection
Any one of type or Topical application forms.
Purposes the most according to claim 7, it is characterised in that described peroral dosage form includes tablet, powder, suspension, breast
Turbid liquid, capsule, granule, coated tablet, pill, liquid, spirit, syrup or limonada;
Optional, described injection type includes water preparation, suspension or solution;
Optional, described Topical application forms includes that ointment, solid, suspension, water preparation, spirit, powder, paste, suppository, gas are molten
Glue, paste, liniment, lotion, enema or Emulsion.
9. include following structural formula:
Novel momordica grosvenori alcohol derivatives monomer (4) compositions preparation for immunomodulating and/or improve microcirculation and/or
Improve the purposes in the health product of quality of life.
10. according to the purposes described in claim 9, it is characterised in that said composition is health product, its comprise treatment and/or
Prevent in novel momordica grosvenori alcohol derivatives monomer (4) described in the claim 1 of effective dose and optional health product acceptable
Carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/089203 WO2017190420A1 (en) | 2016-05-06 | 2016-07-07 | Uses of mogrol derivative monomer and composition thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610298720X | 2016-05-06 | ||
CN201610298720 | 2016-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106188205A true CN106188205A (en) | 2016-12-07 |
CN106188205B CN106188205B (en) | 2017-08-25 |
Family
ID=57465217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610520359.0A Active CN106188205B (en) | 2016-05-06 | 2016-07-04 | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106188205B (en) |
WO (1) | WO2017190420A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017190421A1 (en) * | 2016-05-06 | 2017-11-09 | 深圳以诺生物制药有限公司 | Novel mogrol derivative monomer |
WO2017190422A1 (en) * | 2016-05-06 | 2017-11-09 | 深圳以诺生物制药有限公司 | Method for preparing novel mogrol derivative from total mogroside |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101033244A (en) * | 2007-04-05 | 2007-09-12 | 上海交通大学 | Method of purifying and preparing momordica grosvenori alcohol |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
WO2011014661A2 (en) * | 2009-07-29 | 2011-02-03 | The University Of Chicago | Liver x receptor agonists |
CN105451742B (en) * | 2013-01-07 | 2021-04-06 | 布莱阿姆青年大学 | Methods for reducing cell proliferation and treating certain diseases |
WO2015061686A2 (en) * | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
CN105777837A (en) * | 2016-05-06 | 2016-07-20 | 深圳以诺生物制药有限公司 | Novel Mogrol derivative monomer |
CN105832748B (en) * | 2016-05-06 | 2019-06-07 | 深圳以诺生物制药有限公司 | A method of preparing momordica grosvenori alcohol derivative from momorside |
-
2016
- 2016-07-04 CN CN201610520359.0A patent/CN106188205B/en active Active
- 2016-07-07 WO PCT/CN2016/089203 patent/WO2017190420A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101033244A (en) * | 2007-04-05 | 2007-09-12 | 上海交通大学 | Method of purifying and preparing momordica grosvenori alcohol |
Non-Patent Citations (3)
Title |
---|
MOTOHIKO UKIYA ET AL.: ""Inhibitory Effects of Cucurbitane Glycosides and Other Triterpenoids from the Fruit of Momordica grosvenori on Epstein-Barr Virus Early Antigen Induced by Tumor Promoter 12-O-Tetradecanoylphorbol-13-acetate"", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 * |
杨秀伟 等: ""罗汉果皂苷 Ⅲ 的人肠内细菌生物转化"", 《北京大学学报(医学版)》 * |
陈兵 等: ""罗汉果醇的制备及大鼠体内代谢研究"", 《广西植物》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017190421A1 (en) * | 2016-05-06 | 2017-11-09 | 深圳以诺生物制药有限公司 | Novel mogrol derivative monomer |
WO2017190422A1 (en) * | 2016-05-06 | 2017-11-09 | 深圳以诺生物制药有限公司 | Method for preparing novel mogrol derivative from total mogroside |
Also Published As
Publication number | Publication date |
---|---|
WO2017190420A1 (en) | 2017-11-09 |
CN106188205B (en) | 2017-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101177445B (en) | Novel bufadienolide compound as well as preparation method and uses thereof | |
CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
CN106083972B (en) | A kind of momordica grosvenori alcohol derivatives monomer | |
CN104910240A (en) | Bougainvillea glabra triterpenoid saponin, hpyerglycemic drugs with triterpenoid saponin as active component and preparation method and application thereof | |
CN104707148A (en) | Polyethylene glycol modified glycyrrhetinic acid and curcumin compound used for resisting hepatic carcinoma, and preparation method thereof | |
CN102516344B (en) | Compound with antitumor activity and preparation method and application thereof | |
CN103910740B (en) | Tetrandrine derivant and preparation method thereof and the application in prepared by antitumor drug | |
CN106188205B (en) | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof | |
CN105963307B (en) | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof | |
CN101585858A (en) | Application of glycosylated puerarin derivate and its combination for preventing and treating cardiovascular and cerebrovascular disease | |
CN102526146A (en) | Medicament composition containing ginsenoside and cantharidin and application of medicament composition | |
CN101948453B (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
CN100464760C (en) | Use of cocklebur fruit total glucoside extract in preparing anti inflammation reaction product | |
CN1994352A (en) | Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction | |
CN102961384A (en) | Medical application of przewaquinone A | |
CN106928299A (en) | One class derives from the compound of the root bark of Chinese wolf-berry, its preparation method and the application in terms of hypoglycemic | |
CN102406735A (en) | Immature bitter orange or bitter orange total flavonoid extract decocted and extracted by water and its purpose | |
CN106554349A (en) | Wild anistree new isopentene group replaces C6‑C3Class compound and preparation method thereof, application and its pharmaceutical composition | |
CN115246868A (en) | Application of pentacyclic triterpenoid in treating neurodegenerative diseases | |
CN104892721B (en) | A kind of new 19-demethylation toadpoison lactone compound and the application in preparing anti-tumor medicinal preparation thereof | |
WO2019119675A1 (en) | Sweet potato sitosterol glycoside saturated fatty acid ester, extract, preparation method therefor, and application thereof | |
CN103054921A (en) | Effective component extracted from bupleurum Chinese and application of antidepression activity thereof | |
CN102204919B (en) | Application of bufotalin to preparation of medicament for treating intracranial tumors | |
CN110237081A (en) | Low polarity rare ginsenoside mixture Δ (20-21) PPD/ Δ (20-22) PPD and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |